| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD299 |
| Uniprot No | Q9H2X3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-399aa |
| 氨基酸序列 | MSDSKEPRVQQLGLLEEDPTTSGIRLFPRDFQFQQIHGHKSSTGCLGHGALVLQLLSFMLLAGVLVAILVQVSKVPSSLSQEQSEQDAIYQNLTQLKAAVGELSEKSKLQEIYQELTQLKAAVGELPEKSKLQEIYQELTRLKAAVGELPEKSKLQEIYQELTRLKAAVGELPEKSKLQEIYQELTRLKAAVGELPEKSKLQEIYQELTELKAAVGELPEKSKLQEIYQELTQLKAAVGELPDQSKQQQIYQELTDLKTAFERLCRHCPKDWTFFQGNCYFMSNSQRNWHDSVTACQEVRAQLVVIKTAEEQNFLQLQTSRSNRFSWMGLSDLNQEGTWQWVDGSPLSPSFQRYWNSGEPNNSGNEDCAEFSGSGWNDNRCDVDNYWICKKPAACFRDE |
| 预测分子量 | 45,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD299(CLEC4M/L-SIGN)重组蛋白的3篇参考文献，包含文献名称、作者及摘要概括：
1. **文献名称**: "CLEC4M functions as a receptor for hepatitis C virus glycoprotein E2 and enhances viral infection"
**作者**: Li et al.
**摘要**: 研究揭示了CLEC4M作为C型凝集素受体，通过结合丙肝病毒(HCV)E2糖蛋白促进病毒进入宿主细胞，重组CLEC4M蛋白被用于体外结合实验，证实其与HCV的相互作用机制。
2. **文献名称**: "Structural characterization of L-SIGN/DC-SIGN isoforms in viral recognition"
**作者**: Feinberg et al.
**摘要**: 通过重组CLEC4M蛋白的晶体结构分析，阐明了其与HIV-1 gp120的结合模式，研究强调了该蛋白在病原体识别中的多态性及其免疫调节功能。
3. **文献名称**: "Recombinant CLEC4M mediates SARS-CoV-2 spike protein binding and potentiates viral entry in vitro"
**作者**: Zhang et al.
**摘要**: 利用重组CLEC4M蛋白验证其与SARS-CoV-2刺突蛋白的相互作用，证明其可能作为新冠病毒感染的辅助受体，为抗病毒药物设计提供了潜在靶点。
如需更多文献或扩展内容，可进一步指定研究方向(如结构、功能或应用)。
CD299. also known as L-SIGN (Liver/Lymph Node-Specific Intercellular Adhesion Molecule-3 Grabbing Non-integrin) or CLEC4M, is a C-type lectin receptor primarily expressed on sinusoidal endothelial cells in the liver and lymph nodes. It plays a role in pathogen recognition, immune modulation, and cell-cell adhesion by binding high-mannose glycans on viral envelopes and bacterial surfaces. CD299 is structurally characterized by an extracellular carbohydrate recognition domain (CRD), a neck region, and a transmembrane domain, enabling interactions with pathogens like HIV, SARS-CoV, Ebola virus, and Mycobacterium tuberculosis. Its ability to facilitate viral entry and antigen presentation links it to both host defense and pathogen dissemination mechanisms.
Recombinant CD299 protein is engineered using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional forms of the protein for research and therapeutic development. This technology allows precise control over glycosylation patterns, critical for studying glycan-dependent interactions. Applications include elucidating CD299’s role in viral entry, immune evasion, and inflammatory responses, as well as screening antiviral compounds or designing glycoprotein-based vaccines. Recombinant variants also aid in structural studies to map ligand-binding sites and optimize inhibitors. Additionally, CD299’s involvement in immune tolerance and lymphocyte trafficking highlights its potential as a target for autoimmune or cancer therapies. By providing a consistent, scalable protein source, recombinant CD299 accelerates mechanistic studies and translational efforts, bridging gaps between pathogen biology and therapeutic innovation.
×
